# Drug Farm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/drug-farm

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.drug-farm.com
- Total disclosed funding: $138M
- Latest round: Series D (Jul 13, 2026)
- Investors on record: 17

## About

Based in Shanghai, China and established in 2015, Shanghai Yaoyuan Biotechnology Co., Ltd., dba Drug Farm, is a biotechnology company developing first-in-class drugs for immunological diseases using its mice genetics platform and AI technologies. The company was founded by Tian Xu, Ph.D., a Chair Professor of Genetics and Vice President of Westlake University and Adjunct Professor of Genetics at Yale University. 

In July 2026, Drug Farm raised USD 55 million in series D funding co-led by Pudong Capital and Shanghai Pudong Investment Holding (Group) with participation from Tukar Capital Management, Toposcend Capital, Keyuan Pharm, BioVeda China Fund, YD Capital, State-owned Assets Investment in Jiashan County, Detong Capital, Weidu Capital and BioMetas.

Drug Farm develops multiple first-in-class drugs pipelines of different stages for the treatment of immunological diseases such as DF-006, an oral ALPK1 agonist that effectively activates hepatic innate immunity, and DF-003, an oral ALPK1 kinase inhibitor that targets the treatment of renal disease, cardiovascular disease, and the rare ophthalmic genetic disease ROSAH. The company's R&D relies on its two major platforms, IDInVivo? that uses piggyBac transposon mutagenesis to generate a library of genetic mutations in mice, and MedChem5, a platform for drug molecule design using deep learning technologies. 

The company generates revenue from developing drugs for the treatment of immunological diseases.

The company will use the series D funding to continue advancing its clinical and preclinical R&D pipeline, accelerate global clinical development programs, strengthen regulatory efforts in key markets, and further expand its R&D capabilities.

## Funding rounds

- Series D, Jul 13, 2026, $55M — Detong Capital, BioVeda China Fund, Toposcend Capital, Weidu Capital, Tukar Capital Management, Pudong Capital, State-owned Assets Investment in Jiashan County, Shanghai Pudong Investment Holding (Group), YD Capital, Keyuan Pharm, BioMetas
- Series C, May 16, 2023, $27M — Detong Capital, Weidu Capital, Beida Fund, State-owned Assets Investment in Jiashan County, YD Capital
- Series A, Feb 10, 2021, $56M — Detong Capital, BVCF Capital, South China Venture Capital, ZUIG Investment, Boshi 360, Wuxi AppTec Group

## Investors

- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series A, Series C, Series D
- BVCF Capital — Series A
- South China Venture Capital (https://capitalatlas.ai/funds/south-china-venture-capital) — Series A
- ZUIG Investment (https://capitalatlas.ai/funds/zuig-investment) — Series A
- Boshi 360 — Series A
- Wuxi AppTec Group — Series A
- Weidu Capital (https://capitalatlas.ai/funds/weidu-capital) — Series C, Series D
- Beida Fund (https://capitalatlas.ai/funds/beida-fund) — Series C
- State-owned Assets Investment in Jiashan County — Series C, Series D
- YD Capital — Series C, Series D
- BioVeda China Fund (https://capitalatlas.ai/funds/bioveda-china-fund) — Series D
- Toposcend Capital (https://capitalatlas.ai/funds/toposcend-capital) — Series D
- Tukar Capital Management (https://capitalatlas.ai/funds/tukar-capital-management) — Series D
- Pudong Capital (https://capitalatlas.ai/funds/pudong-capital) — Series D
- Shanghai Pudong Investment Holding (Group) — Series D
- Keyuan Pharm — Series D
- BioMetas — Series D